The AAV capsid plays a crucial role in determining the effectiveness of gene therapy. By engineering AAV capsids, researchers can customize the properties of these vectors to address specific requirements, such as enhancing tissue targeting, reducing immunogenicity, or increasing payload capacity.
Real&Best has created AAV Capsid Libraries for serotypes 2, 5, 6, and 9, carefully screening for variants with diverse tissue tropisms such as the CNS, lungs, kidneys, and muscles. This groundbreaking approach holds enormous promise for developing more potent gene therapies, opening the door to revolutionary treatments that have the potential to change the lives of numerous individuals.
